secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001437749-24-030299
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed to present neflamapimod biomarker and baseline data at CTAD; topline RewinD-LB due Dec 2024
--------------------------------------------------------------------------------

- Two late-breaking oral presentations at CTAD in Madrid (Oct 29 – Nov 1) on neflamapimod for DLB.
- Plasma biomarker data from AscenD-LB Phase 2a study will be presented November 1.
- Baseline data from RewinD-LB Phase 2b study to be featured; CEO says increases confidence in positive outcome.
- Topline data from RewinD-LB Phase 2b study expected in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924030299/0001437749-24-030299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924030299/crvo20240930_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer